Private company

Versant Venture Capital VI, L.P.

American company, incorporated in Delaware. Summary from the record

Last updated Oct 21, 2026.

Overview

HeadquartersDE¹

See how the biggest companies compare on our leaderboards

Corporate structure

Versant Venture Capital VI, L.P. sits at the top of its group. 10 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Versant Venture Capital VI, L.P. DE
- Aligos Therapeutics, Inc. Stake · South San Francisco, California, United States
- Black Diamond Therapeutics, Inc. Stake · Cambridge, Massachusetts
- Century Therapeutics (United States) Stake · Philadelphia, Pennsylvania
- LAVA Therapeutics NV Stake · P7
- LENZ Therapeutics, Inc. Stake · Solana Beach, California
- Monte Rosa Therapeutics Stake · Boston, Massachusetts
- Oyster Point Pharma, Inc. Stake · Princeton, New Jersey
- Passage BIO, Inc. Stake · Philadelphia, Pennsylvania
- Tempest Therapeutics, Inc. Stake · Brisbane, California

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (9 companies). Each entity in the chart links to its source.

Stakes it holds

Versant Venture Capital VI, L.P. has told the SEC it owns more than 5% of 9 companies, latest first (Schedules 13D and 13G).

Tempest Therapeutics, Inc.SCHEDULE 13D/A Feb 11, 2022 to Apr 2, 2026²
Monte Rosa TherapeuticsSCHEDULE 13D/A Nov 9, 2023 to Jan 9, 2026³
LENZ Therapeutics, Inc.SCHEDULE 13D/A Nov 17, 2023 to Nov 10, 2025⁴
LAVA Therapeutics NVSCHEDULE 13D/A Sep 18, 2025 to Sep 23, 2025⁵
Passage BIO, Inc.SC 13D/A Nov 9, 2023 to Aug 9, 2024⁶
Black Diamond Therapeutics, Inc.SC 13D/A Nov 9, 2023 to Aug 8, 2024⁷
Aligos Therapeutics, Inc.SC 13D/A Feb 8, 2024⁸
Century Therapeutics (United States)SC 13G/A Feb 11, 2022 to Feb 8, 2024⁹
Oyster Point Pharma, Inc.SC 13D/A Oct 27, 2021 to Jan 13, 2023¹⁰

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARVersant Venture Capital VI, L.P. filings on SEC EDGAR
2
SEC EDGARVersant Venture Capital VI, L.P. SCHEDULE 13D/A on Tempest Therapeutics, Inc.
3
SEC EDGARVersant Venture Capital VI, L.P. SCHEDULE 13D/A on Monte Rosa Therapeutics
4
SEC EDGARVersant Venture Capital VI, L.P. SCHEDULE 13D/A on LENZ Therapeutics, Inc.
5
SEC EDGARVersant Venture Capital VI, L.P. SCHEDULE 13D/A on LAVA Therapeutics NV
6
SEC EDGARVersant Venture Capital VI, L.P. SC 13D/A on Passage BIO, Inc.
7
SEC EDGARVersant Venture Capital VI, L.P. SC 13D/A on Black Diamond Therapeutics, Inc.
8
SEC EDGARVersant Venture Capital VI, L.P. SC 13D/A on Aligos Therapeutics, Inc.
9
SEC EDGARVersant Venture Capital VI, L.P. SC 13G/A on Century Therapeutics (United States)
10
SEC EDGARVersant Venture Capital VI, L.P. SC 13D/A on Oyster Point Pharma, Inc.